CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xanthus Pharmaceuticals, Inc., a privately-held oncology drug development company, today announced the presentation of data from preclinical studies in which Symadex™ (C-1311) demonstrated potent in vitro and in vivo activity against leukemia cells. The presentation was made in a poster session at the American Society of Hematology 48th Annual Meeting and Exposition in Orlando, Florida.
